Impact of the extent of resection on the survival of patients with lower-grade gliomas using awake brain mapping

Kazuya Motomura (kmotomura@med.nagoya-u.ac.jp)
Nagoya Daigaku Igakubu Fuzoku Byoin
https://orcid.org/0000-0002-4376-1104

Lushun Chalise
Nagoya Daigaku Igakubu Fuzoku Byoin

Fumiharu Ohka
Nagoya Daigaku Igakubu Fuzoku Byoin

Kosuke Aoki
Nagoya Daigaku Igakubu Fuzoku Byoin

Kuniaki Tanahashi
Nagoya Daigaku Igakubu Fuzoku Byoin

Masaki Hirano
Nagoya Daigaku Igakubu Fuzoku Byoin

Tomohide Nishikawa
Nagoya Daigaku Igakubu Fuzoku Byoin

Junya Yamaguchi
Nagoya Daigaku Igakubu Fuzoku Byoin

Hiroyuki Shimizu
Nagoya Daigaku Igakubu Fuzoku Byoin

Toshihiko Wakabayashi
Nagoya Daigaku Igakubu Fuzoku Byoin

Ryuta Saito
Nagoya Daigaku Igakubu Fuzoku Byoin

Research Article

Keywords: awake brain mapping, lower-grade gliomas, progression-free survival, extent of resection, suprtotal resection, IDH-mutant glioma, IDH-wild type glioma

DOI: https://doi.org/10.21203/rs.3.rs-315855/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose

The aim of this study was to assess the effect of the extent of resection (EOR) of tumors on survival in a series of patients with lower-grade gliomas (LGGs) who underwent awake brain mapping.

Methods

We retrospectively analyzed 126 patients with LGGs in the dominant and non-dominant hemisphere who underwent awake brain surgery at the same institution between December 2012 and May 2020.

Results

The median progression-free survival (PFS) rate of patients with LGGs in the group with an EOR > 100%, including supratotal resection (n = 47; median survival [MS], not reached), was significantly higher than that in the group with an EOR < 100% (n = 79; MS, 43.1 months; 95% CI: 37.8–48.4 months; p = 0.04). In patients with diffuse astrocytomas and anaplastic astrocytomas, the group with EOR > 100%, including supratotal resection (n = 25; MS, not reached), demonstrated a significantly better PFS rate than did the group with an EOR < 100% (n = 45; MS, 35.8 months; 95% CI: 19.9–51.6 months; p = 0.03). Supratotal or gross total resection was correlated with better PFS in IDH-mutant type of diffuse astrocytomas and anaplastic astrocytomas (n = 19; MS, not reached vs. n = 35; MS, 40.6 months; 95% CI: 22.3–59.0 months; p = 0.02). By contrast, supratotal or gross total resection was not associated with longer PFS rates in patients with IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas.

Conclusions

It is noteworthy that supratotal or gross total resection significantly correlated with better PFS in IDH-mutant type of WHO grade II and III astrocytic tumors. In light of our finding that EOR did not correlate with PFS in patients with aggressive IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas, we suggest treatments that are more intensive will be needed for the control of these tumors.

Introduction

Lower-grade gliomas (LGGs)—World Health Organization (WHO) grade II and grade III brain tumors are diffusely infiltrative tumors of the central nervous system[1, 2]. This term has recently replaced the specification “low-grade” gliomas, which include grade II gliomas, in clinical practice. Overtime, LGGs typically progress to WHO grade IV tumors, glioblastomas (GBMs), which are malignant tumors with a median survival of only 7.8–31 months, even with aggressive treatment such as surgery and chemoradiotherapy[3, 4]. The classification of LGGs into molecular subtypes in the new WHO 2016 classification has important prognostic implications[5]. In the 2016 classification, isocitrate dehydrogenase (IDH) 1 and 2 mutations are key genetic events in LGGs as well as in GBMs[5].

Surgical tumor resection is the initial first-line treatment to control LGGs, because it can decrease tumor volume and the risk for malignant transformation of LGGs into highly malignant gliomas. Many studies have provided evidence supporting maximum safe surgical resection and early surgical intervention, which prolong survival in
patients with LGGs[6-13]. Although there are no well-designed randomized controlled clinical trials demonstrating a correlation between a higher extent of resection (EOR) and a better clinical prognosis of LGGs, complete radiological resection of LGGs is the currently recommended approach.

The goal of complete tumor resection should be balanced against neurological disturbances including motor, language, and neurocognitive impairments, due to the infiltrative behavior of LGGs[14, 15]. To ensure both maximal safe resection and preservation of these neurological functions, the use of intraoperative awake brain mapping techniques has been proposed as the reference standard strategy for patients with LGGs[16-20]. Awake surgery allows for the maximum degree of resection while determining functional boundaries, using both cortical and subcortical functional mapping[17, 21]. When functional boundaries are observed within the tumor mass, resection can be subtotal or partial. If the functional boundaries lie outside the tumor region, gross total or supratotal resection can be achieved. Extended tumor resection beyond the margins of the abnormal magnetic resonance imaging (MRI)-verified area is known as supratotal resection[22, 23]. Because there is only limited evidence for an effect of supratotal or gross total removal on the control of the tumor and histological malignant transformation[22, 24, 25], the oncological impact of the EOR on survival is still uncertain. Furthermore, it is unclear how far around the tumor mass resection can be safely extended to prolong the survival of patients with LGGs. There is also concern regarding whether an improvement in survival due to massive tumor resection depends on the patient’s molecular genetic status, such as IDH1/2 mutations in patients with IDH-mutant type or IDH-wild type of LGGs.

In the present study, we performed awake brain mapping with cortical and subcortical stimulation for LGGs in order to achieve supratotal resection whenever possible, while determining the functional brain tissue boundaries beyond the tumor margins. We assessed the effect of tumor EOR on survival in a series of 126 consecutive patients with LGGs who all underwent awake brain mapping. In addition, we performed a subanalysis to assess the association between clinical outcome and tumor EOR in the subtypes of LGGs classified according to the molecular genetic status after awake surgery.

**Materials And Methods**

**Study design**

This is a retrospective analysis of 126 consecutive patients with LGGs. All underwent awake surgery with intraoperative direct electrical stimulation at Nagoya University Hospital (Nagoya, Japan) between December 2012 and May 2020. Patient data on clinical information and outcomes were collected and analyzed. The Ethics Committee at Nagoya University Hospital approved this retrospective data evaluation and the experimental design of the study (approval number: 2020-0079). We obtained written informed consent prior to the surgical mapping procedure from all participants included in the study.

**Pre- and postsurgical neuroradiological examination**

We performed preoperative MRI, including three-dimensional T1-weighted imaging, conventional MRI (T1-, T2-, and FLAIR-weighted imaging), and diffusion-weighted imaging, using a 3.0 Tesla scanner (Trio, Siemens, Germany). To assess the EOR, MRI (T1-weighted, T2-weighted, and FLAIR-weighted) was also conducted at 1 week and 3 months postoperatively and at every 3 months thereafter.
Intraoperative awake brain mapping technique

All 126 patients underwent awake brain mapping with direct electrical stimulation using an asleep-awake-asleep protocol, as previously described[17, 23, 26-29]. In brief, we performed a craniotomy under general anesthesia. In the first stage, the tumor margins and cerebral sulcus and gyrus were identified using a neuro-navigational system, and letter tags were placed along the tumor boundaries on the cortical surface before the brain shifts occurred. Cortical mapping with direct electrical stimulation was then performed to detect the motor and language areas. We used a bipolar stimulator with a 2-mm diameter and a 5-mm interelectrode distance (Unique Medical, Osaka, Japan) to deliver a biphasic current (pulse frequency, 60 Hz: single pulse phase duration, 0.5 ms). The Neuromaster MEE1200 (Nihon Kohden, Tokyo, Japan) was used for intraoperative neurological monitoring during the awake surgery.

The stimulation intensity used for individual patients was determined by increasing the amplitude in 0.5-mA increments from a baseline of 1.0 mA until a functional response was elicited. Maximum individual intensities ranged from 2 mA to 8 mA. After determining the optimal stimulation threshold, cortical mapping was performed by applying electrical stimulations of the same intensity over the whole exposed cortical area surface. This stimulation threshold was then also used for subcortical mapping. Using strip electrodes, continuous digital electrocorticograms (ECoGs) were monitored to detect after-discharges during direct electrical stimulation and tumor resection.

For language mapping, the patients were asked to perform counting and picture-naming tasks, with the goal to identify the cortical language sites and subcortical fibers using direct brain stimulations[23]. The type of observed language disturbances was determined based on a detailed classification for language disorders, including speech arrest, anomia, dysarthria, anarthria, speech slowness, initiation trouble, perseveration, and paraphasia.

After the cortical mapping was complete, tumor resection was initiated using the subpial resection technique. We removed the tumor to the level of the white matter, while frequently checking the patient's response using subcortical electrical stimulation. Subcortical mapping enabled us to determine the functional boundaries between the tumor and white matter pathways. Thus, tumor removal was accomplished according to the cortical or subcortical functional boundaries in all patients, while aiming for achieving supratotal resection whenever possible. After tumor resection, intraoperative MRI was routinely performed to assess the EOR of the tumor using a 0.4 Tesla vertical field MR scanner (Aperto Inspire, Hitachi, Tokyo, Japan) set up in the operating room of the Brain THEATER at Nagoya University Hospital.

Degree of tumor resection and volumetric analysis

Volumetric analysis was performed using the iPlan® cranial planning software included in the BrainLAB iPlan® Cranial version 2.6 and 3.0[30] (German HealthCare Export Group, Bonn, Germany). The pre- and postoperative tumor volumes were measured in all patients to estimate the EOR using contrast T1-weighted or FLAIR-weighted MRI data obtained before and after tumor removal. If the tumor was not enhanced or partially enhanced on MRI, the EOR was evaluated based on residual high-intensity lesions on FLAIR-weighted MRI. On the other hand, if the tumor was enhanced on MRI, the EOR of the tumor was calculated based on the residual enhanced tumor. The EOR was calculated using the difference between preoperative and postoperative tumor volumes:
(preoperative tumor volume – postoperative tumor volume) / preoperative tumor volume[6]. Volumetric EOR was categorized as follows: supratotal resection, EOR > 100%; gross total resection, EOR = 100%; subtotal resection, EOR ≥ 90% to < 100%; and partial resection, EOR < 90%. A supratotal resection was defined as tumor resection extending beyond the MRI-verified abnormal area or the complete removal of any abnormality, with the postoperative cavity volume being larger than the preoperative tumor volume[22, 25, 31]. This was also defined as a postoperative tumor cavity/preoperative tumor volume >100%.

Tumor progression was defined as newly detected areas of contrast enhancement and/or an obvious increase in the FLAIR signal abnormality on follow-up MRI relative to the baseline postoperative MRI obtained within 72 hours of the operation.

**Adjuvant therapy protocol**

Further treatment of grade II gliomas that underwent total or supratotal resection was based on observation. When more than 10% of the tumor was left, chemotherapy such as temozolomide (TMZ) was applied as adjuvant treatment.

For grade III gliomas, initial adjuvant treatment included focal external-beam radiation therapy by conventional radiation planning to approximately 60 Gy (±5% total dose), with daily concurrent TMZ at 75 mg/m² throughout the course of the radiation therapy. This was followed by adjuvant temozolomide according to the Stupp protocol[32].

**Direct DNA sequencing for IDH1 and IDH2 mutations**

Direct sequencing of IDH1 and IDH2 was conducted as previously described[33]. A 129-bp fragment spanning the sequence encoding the catalytic domain of IDH1, including codon 132, and a 150-bp fragment spanning the sequence encoding the catalytic domain of IDH2, including codon 172, were amplified for IDH sequencing.

**Statistical analyses**

All statistical analyses were conducted using SPSS version 27.0 (IBM Corporation, Armonk, NY, USA) for Windows (Microsoft Corporation, Redmond, WA, USA). Survival was estimated using the Kaplan–Meier method, and the log-rank test was used to assess survival differences among groups. Progression-free survival (PFS) was calculated from the day of the first surgery till the occurrence of true tumor progression, death, or the end of the follow-up. Overall survival (OS) was calculated from the day of the first surgery until death or the end of the follow-up.

Factors influencing PFS in our cohort of patients with LGGs during awake brain surgery were investigated using univariate and multivariate Cox proportional hazards models adjusted for major clinical prognostic factors, including age at diagnosis (>40 years vs. ≤40 years), histologic type (astrocytic vs. oligodendrogial), WHO grade (grade III gliomas vs. grade II gliomas), tumor location (frontal regions vs. other regions), IDH1 or IDH2 status (mutation or wild type), final EOR (>100% vs. <100%), chemotherapy (+ vs. -), and chemoradiotherapy (+ vs. -). The covariates and the independent variables that showed significant differences in the univariate analysis were used for the analysis. The remaining factors in the multivariate Cox proportional hazards model (p < 0.05) were considered to be independent predictors of PFS.
Results

Patients

Between December 2012 and May 2020, a total of 126 consecutive patients (74 males, 52 females) who underwent awake surgery for LGGs of the dominant and non-dominant hemisphere were enrolled in this study. The median follow-up time was 33.0 months (range, 0.3–89.9 months). The patients' clinical characteristics are summarized in Table 1. The mean age at the time of awake surgery was 42.8 years (range, 17–76 years). The tumors were located in the left hemisphere in 88 cases (69.8%) and in the right hemisphere in 38 cases (30.2%). The majority of the tumors were located in the frontal lobe (n = 73, 57.9%), followed by the insular lobe (n = 27, 21.4%), the temporal lobe (n = 13, 10.3%), the parietal lobe (n = 12, 9.5%), and the occipital lobe (n = 1, 0.8%). Histologically, the present study consisted of all patients with LGGs, including 91 WHO grade II gliomas (52 diffuse astrocytomas, 39 oligodendrogliomas) and 35 WHO grade III gliomas (18 anaplastic astrocytomas, 17 anaplastic oligodendrogliomas). IDH1 or IDH2 mutations were observed in 105 patients (83.3%), while IDH1 or IDH2 wild types were identified in 21 patients (16.7%). Ring-like or nodular enhancement by gadolinium MRI was observed in 10 (28.6%) of 35 patients with WHO grade III gliomas. Preoperative mean tumor volume was 49.5 cm$^3$ (range, 1.2–196.4 cm$^3$). The median EOR was 93.1% in all patients. The median EOR in patients with dominant left tumors and in patients with non-dominant right tumors were 91.1% and 100%, respectively. A final EOR > 100% (supratotal resection) was achieved in 15 patients (11.9%), an EOR = 100% (gross total resection) in 32 patients (25.4%), an EOR ≥ 90% and < 100% (subtotal resection) in 27 (21.4%) patients, and an EOR < 90% in 52 (41.3%) patients.

Postoperative neurological outcomes

Table 2 shows the summary of transient or permanent postoperative neurological deficits, including motor and speech disturbances, according to main tumor location. During the postoperative course, 47 (37.3%) patients exhibited new transient speech disturbances, 27 (21.4%) developed transient motor disorders, five (4.0%) exhibited permanent speech deficits, and nine (7.1%) had permanent motor deficits. Among the 73 patients with frontal tumors, 24 (32.9%) exhibited transient speech disturbances and 17 (23.3%) developed transient motor disturbances. Of these 73 patients, two (2.7%) demonstrated persistent speech deficits and three (4.1%) had permanent motor deficits. By contrast, three of the 27 patients with insular tumors (11.1%) exhibited permanent speech disorders and four (14.8%) had permanent motor deficits.

Survival and supratotal or gross total resection in LGGs

We analyzed whether supratotal (EOR > 100%) or gross (EOR = 100%) total resection affected the survival of our 126 consecutive patients. The Kaplan–Meier estimates for PFS according to EOR classes for all patients are shown in Figure 1. The median PFS rate of the patients in the group with an EOR ≥ 100 %, including supratotal resection (n = 47; median survival, not reached), was significantly higher than that in the group with an EOR < 100% (n = 79; median survival, 43.1 months; 95% CI: 37.8–48.4 months; p = 0.04; Fig 1). There were no significant differences in the median PFS rate between the patients in the group with EOR >100 % (n = 15; median survival, not reached) and those in the group with EOR = 100% (n = 32; median survival, not reached; p = 0.1). Furthermore, there were no significant differences in the median OS rates based on the EOR. In patients with diffuse astrocytomas and anaplastic astrocytomas, the group with an EOR ≥ 100 %, including supratotal...
resection (n = 25; median survival, not reached), demonstrated a significantly better PFS rate than the group with an EOR < 100% (n = 45; median survival, 35.8 months; 95% CI: 19.9–51.6 months; p = 0.03; Fig 2). The median OS rates of patients with diffuse astrocytomas and anaplastic astrocytomas showed no difference between groups classified according to EOR. By contrast, neither the median PFS nor the median OS significantly differed across EOR classes in patients with oligodendrogliomas and anaplastic oligodendrogliomas.

**Benefits of supratotal or gross total resection for patients with \( \text{IDH} \)-mutant type of diffuse astrocytomas and anaplastic astrocytomas**

We next investigated the prognostic correlations between supratotal or gross total resection and \( \text{IDH1/IDH2} \) mutations in diffuse astrocytomas and anaplastic astrocytomas. It is noteworthy that supratotal or gross total resection was correlated with better PFS in \( \text{IDH} \)-mutant type of diffuse astrocytomas and anaplastic astrocytomas (n = 19; median survival, not reached vs. n = 35; median survival, 40.6 months; 95% CI: 22.3–59.0 months; p = 0.02). By contrast, supratotal or gross total resection was not associated with longer PFS in patients in \( \text{IDH} \)-wild type of diffuse astrocytomas and anaplastic astrocytomas.

**Factors influencing progression-free survival in patients with LGGs during awake brain surgery**

Our univariate analysis shows that PFS in patients with LGGs was significantly associated with \( \text{IDH1 or IDH2} \) status (mutation vs. wild type, hazard ratio [HR] = 0.39, 95% CI: 0.20–0.77, p = 0.006), final EOR (≥100 % vs. <100 %, HR = 0.43, 95% CI: 0.19–0.98, p = 0.04), and chemotherapy (+ vs. -, HR = 1.97, 95% CI: 1.03–3.79, p = 0.04; Table 3).

We further established multivariate Cox proportional hazards models for the factors influencing PFS in patients with LGGs using the following prognostic factors: \( \text{IDH1 or IDH2} \) status, final EOR, and chemotherapy. These multivariate models were subsequently adjusted to estimate the HR associated with PFS in our patients. Notably, the multivariate models also showed that PFS rates were significantly related to \( \text{IDH1} \) or \( \text{IDH2} \) status (mutation vs. wild type, HR = 0.30, 95% CI: 0.15–0.60, p = 0.001) and final EOR (≥100 % vs. <100 %, HR = 0.37, 95% CI: 0.16–0.87, p = 0.02; Table 3).

**Discussion**

Large observational studies based on the objective evaluation of the EOR for gliomas have shown that maximal resection is significantly associated with favorable clinical outcomes for WHO grade II gliomas[6-11, 34]. One retrospective study of 216 patients with WHO grade II gliomas demonstrated that patients with an EOR > 90% had a 5-year OS rate of 97%, whereas patients with an EOR < 90% had a 5-year OS rate of 76%[6]. Jakola et al. reported on a retrospective population-based parallel cohort of WHO grade II gliomas in Norway, comparing two hospitals with distinct treatment strategies. One hospital strategy favored early surgical tumor resection, while the other preferred biopsy and observation for WHO grade II gliomas. Notably, this study revealed a significant increase in survival in patients in the “early surgical resection” group[9, 10], with a 5-year OS rate of 74% compared to a rate of 60% in the “biopsy and observation” group. Furthermore, another study reported a significant survival benefit for patients under “early tumor resection” management compared to those under “biopsy management” (5-year OS: 82% vs. 54%)[11], at two different departments acting independently at the
same university hospital. This suggests that glioma surgeons should aim for maximal safe resection by increasing the tumor EOR in order to prolong survival in patients with WHO grade II gliomas. A large European phase III clinical trial (EORTC-26951) found that the extent of surgery was significantly related to survival in WHO grade III anaplastic oligodendrogial tumors[35]. Nomiya et al. retrospectively estimated the prognostic factors for 170 patients with WHO grade III anaplastic astrocytoma[36]. The median survival times of their patients, classified into total resection, subtotal resection, partial resection, and biopsy-only groups, were 86.4, 61.6, 22.9, and 23.4 months, respectively. The authors emphasized that the extent of surgery is the most powerful prognostic factor in the treatment of WHO grade III anaplastic astrocytoma. Kawaguchi et al. revealed the importance of surgical resection by investigating 124 consecutive patients newly diagnosed with WHO grade III gliomas[37]. Among these patients without 1p/19q co-deletion, those with gross total removal had significantly longer median overall survival times than those without gross total removal (median survival: not reached versus 77 months). Our results indicate that, similarly, an EOR ≥ 100 %, including supratotal resection, is significantly associated with better PFS rates in patients with LGGs (WHO grade II and III gliomas) ($p = 0.04$, Fig. 1). These results support the notion that maximal safe resection is a crucial prognostic factor for improving the survival of patients with LGGs.

Duffau et al. firstly reported that supratotal resection improves the outcome of patients with WHO grade II gliomas who have undergone awake mapping, after a mean follow-up of 11 years[22]. These results suggest that supratotal resection, extending beyond the abnormalities detected by FLAIR-weighted MRI, provides a survival benefit, because tumor cells might invade sites 10–20 mm away from the tumor boundaries on MRI[38]. Since a greater EOR, such as that achieved by gross total or supratotal surgical tumor resection, could significantly increase survival in patients with WHO grade II gliomas, we tried to achieve supratotal resection of the functional boundaries whenever possible, with the aid of awake functional mapping. We previously reported on the efficacy of awake brain surgery for the supratotal resection of diffuse frontal LGGs, while motor, language, and neurocognitive functions are preserved[23].

Recently, Rossi et al. presented a retrospective review of 319 IDH-mutated LGGs in which supratotal resection was significantly related to survival, independently of molecular subtypes and WHO grades[24]. The authors found that PFS rates were significantly higher in patients with IDH-mutated WHO grade II and III astrocytomas or oligodendrogliomas who underwent supratotal resection than in those who underwent total resection. Moreover, supratotal resection was significantly associated with a reduced rate of malignant transformation and a better OS. The present study found that supratotal or gross total resection was significantly associated with better PFS in IDH-mutant type of diffuse astrocytomas and anaplastic astrocytomas, but not in IDH-wild type.

Furthermore, our results revealed no significant correlations between PFS and supratotal or gross total resection in patients with oligodendrogliomas and anaplastic oligodendrogliomas. This difference in results might stem from a small number of patients with oligodendrogliomas (56 cases of WHO grade II and III oligodendrogliomas) in our series compared to the earlier study by Rossi et al. (180 cases of WHO grade II and III oligodendrogliomas). Moreover, WHO grade III anaplastic gliomas have been recommended to be treated by maximal safe resection followed by radiotherapy and adjuvant PCV (procarbazine, lomustine, and vincristine) [35, 39]. Considering that adjuvant chemotherapy is an independent prognostic factor for improved survival of WHO grade III anaplastic oligodendroglioma[40], the EOR might not play an important role in the long-term outcome of oligodendrogliomas and anaplastic oligodendrogliomas. In addition, our study did not reveal a significant effect of supratotal or gross total resection in patients with IDH-wild type of diffuse astrocytomas
and anaplastic astrocytomas. Recent studies suggested that these IDH-wild types of astrocytic tumors belong to completely different entities and therefore require different tumor management[41].

Our study reveals that tumor resection with awake functional mapping is associated with a reduction in late severe permanent neurological deficits in patients with LGGs, despite an early increase in transient functional deficits. In our study, late permanent speech and motor disturbances were observed in 4.0% and 7.1% of patients, respectively. By contrast, early transient speech and motor disturbances were observed in 37.3% and 21.4% of patients, respectively (Table 2). Compared to the total postoperative neurological deficits, however, late permanent speech and motor disturbances in insular tumor cases were relatively common (11.1% and 14.8% of patients, respectively), which indicates that they present a surgical challenge regardless of the use of awake functional mapping. These observed transient neurological disturbances, due to the proximity of critical normal brain structures to the tumor cavity, usually disappeared within a few weeks or months after tumor resection. Awake mapping enables more extensive tumor resection for better tumor control, while reliably identifying critical normal brain structures so that permanent neurological deficits can be avoided.

Although the current study provides novel information regarding the impact of supratotal or gross total resection with awake mapping on the survival of patients with LGGs, our results are limited compared to those of prospective clinical trials, as retrospective studies may be influenced by unrecognized biases. Most importantly, the survival improvement associated with EOR ≥ 100% may be due to biases from differential tumor aggressiveness in non-resectable or easily resectable portions of the brain. Furthermore, the present study was based on a small number of tumor cases; therefore, a larger cohort study is needed to further establish the effect of supratotal or gross total resection during awake surgery using cortical and direct axonal electrical stimulation. Thus, further accumulation of evidence for this surgical strategy for LGGs will help the improvement of the treatment of this disease and hopefully develop it into a novel therapy.

**Conclusions**

The present study demonstrates the significant association of tumor EOR with survival in patients with LGGs. It is noteworthy that supratotal or gross total resection significantly correlated with better PFS in IDH-mutant type of WHO grade II and III astrocytic tumors. In light of our finding that EOR did not correlate with PFS in patients with aggressive IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas, we suggest treatments that are more intensive will be needed for the control of these tumors.

**Declarations**

- **Funding**

This work was supported by a Grant-in-Aid for Scientific Research (C) awarded to K.M. (No. 17K10862) from the Japan Society for the Promotion of Science (JSPS). We have no financial disclosures or conflicts of interest to declare.

- **Conflicts of interest**

The authors declare that they have no conflicts of interest.
• **Availability of data and material (data transparency)**

The data in the current study are available from the corresponding author on reasonable request.

• **Code availability (software application or custom code)**

Not applicable

• **Authors' contributions**

Experimental design: Kazuya Motomura, Toshihiko Wakabayashi, Ryuta Saito

Collection and assembly of data: Lushun Chalise, Kuniaki Tanahashi, Masaki Hirano, Tomohide Nishikawa. Junya Yamaguchi, Hiroyuki Shimizu

Analysis and interpretation of the data: Kazuya Motomura, Fumiharu Ohka, Kosuke Aoki, Ryuta Saito

Manuscript writing: Kazuya Motomura

Final approval of manuscript: all authors.

• **Ethics approval**

The Ethics Committee at Nagoya University Hospital approved this retrospective data evaluation and the experimental design of the study (approval number: 2020-0079).

• **Consent to participate (include appropriate statements)**

Patient informed consents were waived due to the retrospective nature of the study.

• **Consent for publication (include appropriate statements)**

Patient informed consents were waived due to the retrospective nature of the study.

**Acknowledgments**

The authors thank Mr. Hiroyasu Yamamoto, Mr. Kyohei Koyama, Mr. Daisuke Hara, and Mr. Yasuyuki Matsui (Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan) for their technical assistance.

**References**

1. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Satot-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47: 458-468 doi:10.1038/ng.3273

2. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M,
Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A (2017) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol doi:10.1093/neuonc/nox132

3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899 doi:10.1158/0008-5472.CAN-04-1337

4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773 doi:10.1056/NEJMoa0808710

5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131: 803-820 doi:10.1007/s00401-016-1545-1

6. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26: 1338-1345 doi:10.1200/JCO.2007.13.9337

7. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 753-764; discussion 264-756 doi:10.1227/01.neu.0000318159.21731.cf

8. Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effenterre R, Capelle L (2005) Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76: 845-851 doi:10.1136/jnnp.2004.048520

9. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, Solheim O (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308: 1881-1888 doi:10.1001/jama.2012.12807

10. Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28: 1942-1948 doi:10.1093/annonc/mdx230

11. Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen VA, Weyerbrock A, Reinacher PC (2016) Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy. Sci Rep 6: 32286 doi:10.1038/srep32286

12. Hervey-Jumper SL, Berger MS (2019) Evidence for Improving Outcome Through Extent of Resection. Neurosurg Clin N Am 30: 85-93 doi:10.1016/j.nec.2018.08.005

13. Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M (2012) Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg 117: 1039-1052 doi:10.3171/2012.8.JNS12393

14. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42: 1044-1055; discussion 1055-1046
15. Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100: 2622-2626 doi:10.1002/cncr.20297

16. Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358: 18-27 doi:10.1056/NEJMoa067819

17. Duffau H, Peggy Gatignol ST, Mandonnet E, Capelle L, Taillandier L (2008) Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg 109: 461-471 doi:10.3171/JNS/2008/109/9/0461

18. De Witt Hamer PC, Robles SG, Zwiderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30: 2559-2565 doi:10.1200/JCO.2011.38.4818

19. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 125: 503-530 doi:10.1007/s11060-015-1867-1

20. Buckner J, Giannini C, Eckel-Passow J, Lachance D, Parney I, Laack N, Jenkins R (2017) Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. Nat Rev Neurol 13: 340-351 doi:10.1038/nrneurol.2017.54

21. Duffau H (2015) Stimulation mapping of white matter tracts to study brain functional connectivity. Nat Rev Neurol 11: 255-265 doi:10.1038/nrneurol.2015.51

22. Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien) 158: 51-58 doi:10.1007/s00701-015-2621-3

23. Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Wakabayashi T, Natsume A (2018) Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions. World Neurosurg 119: 30-39 doi:10.1016/j.wneu.2018.07.193

24. Rossi M, Gay L, Ambrogi F, Nibali MC, Sciortino T, Puglisi G, Leonetti A, Mocellini C, Caroli M, Cordera S, Simonelli M, Pessina F, Navarria P, Pace A, Soffietti R, Ruda R, Riva M, Bello L (2020) Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas. Neuro Oncol doi:10.1093/neuonc/noaa225

25. Rossi M, Ambrogi F, Gay L, Gallucci M, Conti Nibali M, Leonetti A, Puglisi G, Sciortino T, Howells H, Riva M, Pessina F, Navarria P, Franzese C, Simonelli M, Ruda R, Bello L (2019) Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. J Neurosurg: 1-14 doi:10.3171/2019.2.JNS183408

26. Motomura K, Fujii M, Maesawa S, Kuramitsu S, Natsume A, Wakabayashi T (2014) Association of dorsal inferior frontooccipital fasciculus fibers in the deep parietal lobe with both reading and writing processes: a brain mapping study. J Neurosurg 121: 142-148 doi:10.3171/2014.2.JNS131234

27. Iijima K, Motomura K, Chalise L, Hirano M, Natsume A, Wakabayashi T (2017) Efficacy of the transtemporal approach with awake brain mapping to reach the dominant posteromedial temporal lesions. Acta Neurochir (Wien) 159: 177-184 doi:10.1007/s00701-016-3035-6
28. Motomura K, Natsume A, Iijima K, Kuramitsu S, Fujii M, Yamamoto T, Maesawa S, Sugiura J, Wakabayashi T (2017) Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas associated with eloquent areas. J Neurosurg 127: 790-797 doi:10.3171/2016.9.JNS16152

29. Motomura K, Takeuchi H, Nojima I, Aoki K, Chalise L, Iijima K, Wakabayashi T, Natsume A (2020) Navigated repetitive transcranial magnetic stimulation as preoperative assessment in patients with brain tumors. Sci Rep 10: 9044 doi:10.1038/s41598-020-65944-8

30. Nimsky C, Ganslandt O, Fahlbusch R (2007) Implementation of fiber tract navigation. Neurosurgery 61: 306-317; discussion 317-308 doi:10.1227/01.neu.0000279224.83998.7d

31. Yordanova YN, Moritz-Gasser S, Duffau H (2011) Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg 115: 232-239 doi:10.3171/2011.3.JNS10133

32. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 doi:10.1056/NEJMoa043330

33. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T (2011) Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730 doi:10.1002/cncr.25637

34. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64: 581-587

35. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijsse CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722 doi:10.1200/JCO.2005.04.6078

36. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106: 575-581 doi:10.3171/jns.2007.106.4.575

37. Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Nakamori M, Kumabe T, Tominaga T (2016) Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129: 505-514 doi:10.1007/s11060-016-2201-2

38. Pallud J, Varlet P, Devaux B, Geha S, Badoual M, Deroulers C, Page P, Dezamis E, Daumas-Duport C, Roux FX (2010) Diffuse low-grade oligodendroglialomas extend beyond MRI-defined abnormalities. Neurology 74: 1724-1731 doi:10.1212/WNL.0b013e3181e04264

39. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijsse CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly
Tables

Table 1. Clinical characteristics
| Parameters                          | No. of patients (n=126) | %     |
|------------------------------------|------------------------|-------|
| Age (years)                        |                        |       |
| mean                               | 42.8                   |       |
| median                             | 41.5                   |       |
| range                              | 17-76                  |       |
| Sex                                |                        |       |
| male                               | 74                     | 58.7  |
| female                             | 52                     | 41.3  |
| Side of lesion                     |                        |       |
| left                               | 88                     | 69.8  |
| right                              | 38                     | 30.2  |
| Tumor location                     |                        |       |
| frontal                            | 73                     | 57.9  |
| insular                            | 27                     | 21.4  |
| temporal                           | 13                     | 10.3  |
| parietal                           | 12                     | 9.5   |
| occipital                          | 1                      | 0.8   |
| Histologic type                    |                        |       |
| diffuse astrocytoma (DA)           | 52                     | 41.3  |
| oligodendroglioma (OG)             | 39                     | 31.0  |
| anaplastic astrocytoma (AA)        | 18                     | 14.3  |
| anaplastic oligodendroglioma (AO)  | 17                     | 13.5  |
| IDH1 or IDH2 status                |                        |       |
| wild type                          | 21                     | 16.7  |
| mutation                           | 105                    | 83.3  |
| Ring-like or nodular enhancements on MRI |                  |       |
| +                                  | 10                     | 7.9   |
| -                                  | 116                    | 92.1  |
| Tumor volume (cm$^3$)              |                        |       |
| mean                               | 49.5                   |       |
| range                              | 1.2-196.4              |       |
| Final extent of resection          |                        |       |
| Median (%)                         | 93.1                   |       |
| >100% (= supratotal resection)     | 15                     | 11.9  |
| 100% (= gross total resection)     | 32                     | 25.4  |
| ≥90%, <100% (= subtotal resection) | 27                     | 21.4  |
| <90% (= partial resection)         | 52                     | 41.3  |
| Adjuvant therapy                   |                        |       |
| chemoradiotherapy                  | 29                     | 23.0  |
| chemotherapy only                  | 10                     | 7.9   |
| none                               | 87                     | 69.0  |

**Table 2.** The summary of postoperative neurological deficit and tumor location
| Tumor location | No. of Patients (%) | Patients with transient speech disturbance (%) | Patients with transient motor disturbance (%) | Patients with permanent speech disturbance (%) | Patients with permanent motor disturbance (%) |
|----------------|---------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Frontal        | 73                  | 24 (32.9)                                     | 17 (23.3)                                     | 2 (2.7)                                       | 3 (4.1)                                       |
| Insular mainly | 27                  | 17 (63.0)                                     | 8 (29.6)                                      | 3 (11.1)                                      | 4 (14.8)                                      |
| Temporal       | 13                  | 3 (23.1)                                      | 1 (7.7)                                       | 0 (0)                                         | 1 (7.7)                                       |
| Parietal       | 12                  | 3 (25.0)                                      | 1 (8.3)                                       | 0 (0)                                         | 1 (8.3)                                       |
| Occipital      | 1                   | 0 (0)                                         | 0 (0)                                         | 0 (0)                                         | 0 (0)                                         |
| **Total**      | **126**             | **47 (37.3)**                                 | **27 (21.4)**                                 | **5 (4.0)**                                   | **9 (7.1)**                                   |

Table 3. Univariate and multivariate Cox proportional hazards models for the factors influencing PFS in patients with lower grade gliomas

| Predictors of PFS in the subgroup of patients | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
| variable                                      | HR             | 95%CI      | p    | HR     | 95%CI      | p    |
| Age, years                                    |                 |             |     |       |             |     |
| <40                                           | 1               |             |     |       |             |     |
| ≥40                                           | 0.89            | 0.49 to 1.62 | 0.70 |       |             |     |
| Histologic type                               |                 |             |     |       |             |     |
| Oligodendrogial                               |                 |             |     |       |             |     |
| Astrocytic                                    | 1.52            | 0.80 to 2.87 | 0.20 |       |             |     |
| WHO grade                                     |                 |             |     |       |             |     |
| Grade II                                      |                 |             |     |       |             |     |
| Grade III                                     | 1.54            | 0.79 to 3.00 | 0.21 |       |             |     |
| Tumor location                                |                 |             |     |       |             |     |
| Other regions                                 |                 |             |     |       |             |     |
| Frontal regions                               | 0.64            | 0.35 to 1.17 | 0.14 |       |             |     |
| IDH1 or IDH2 status                           |                 |             |     |       |             |     |
| Wild type                                     |                 |             |     |       |             |     |
| Mutation                                      | 0.39            | 0.20 to 0.77 | 0.006 | 0.30 | 0.15 to 0.60 | 0.001 |
| Final EOR                                     |                 |             |     |       |             |     |
| <100 %                                        | 0.43            | 0.19 to 0.98 | 0.04 | 0.37 | 0.16 to 0.87 | 0.02 |
| ≥100 %,                                       |                 |             |     |       |             |     |
| Chemotherapy                                  |                 |             |     |       |             |     |
| +                                             | 1.97            | 1.03 to 3.79 | 0.04 | 1.80 | 0.92 to 3.51 | 0.09 |
| Chemoradiotherapy                             |                 |             |     |       |             |     |
| +                                             | 1.63            | 0.82 to 3.25 | 0.16 |       |             |     |

Abbreviation: PFS; progression free survival, WHO; World Health Organization, IDH; isocitrate dehydrogenase, EOR; extent of resection, HR; hazard ratio, CI; confidence interval
Figures

![Kaplan–Meier curves showing progression-free survival (PFS) for the entire cohort according to the extent of resection (EOR) ≥ 100% or < 100% in all patients with lower-grade gliomas (LGGs)]

Figure 1. Motomura et al.

Figure 1

- Kaplan–Meier curves showing progression-free survival (PFS) for the entire cohort according to the extent of resection (EOR) ≥ 100% or < 100% in all patients with lower-grade gliomas (LGGs)
Figure 2

Kaplan–Meier curves showing progression-free survival (PFS) according to the extent of resection (EOR) ≥ 100% or < 100% in patients with diffuse astrocytomas and anaplastic astrocytomas

Figure 3A. Motomura et al.

Figure 3B. Motomura et al.
Figure 3

Fig. 3A. Kaplan–Meier curves showing progression-free survival (PFS) according to the extent of resection (EOR) $\geq 100\%$ or $< 100\%$ in IDH-mutant type of diffuse astrocytomas and anaplastic astrocytomas. Fig. 3B. Kaplan-Meier curves showing progression-free survival (PFS) according to extent of resection (EOR) $\geq 100\%$ or $< 100\%$ in IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas.